open access
The genes expression status of inflammatory determinants following the oral administration of Mannuronic acid in patients with rheumatoid arthritis
Affiliations- Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
- Department of Rheumatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Rheumatic Disease Research Center. Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Rheumatology, Shahid Sadooghi Hospital, Yazd University of Medical Sciences, Yazd, Iran
- Keck Medicine Glendale, California, United States
- Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
open access
Abstract
Introduction: Rheumatoid arthritis (RA) is a progressive multifactorial inflammatory disorder. According to numerous evidence, pro-inflammatory markers such as TNF-a, IL-6, IL-22, MYD88 and TLR2 play a substantial role in the pathogenesis and persistence of this disease. B-D-Mannuronic acid (M2000) is a new immunosuppressive drug whose therapeutic effects have been approved in several clinical trials and the results of the phase III clinical trial of this drug in RA patients were potent and efficient. Therefore, the present investigation was designed to evaluate its anti-inflammatory effects on the expression of mentioned factors in RA patients.
Material and methods: This research was carried out on 12 healthy individuals and 12 patients with RA and M2000 was administered to the patients orally at a dose of 500 mg twice daily for 12 weeks. The peripheral blood mononuclear cells (PBMCs) were collected from the patients before and after treatment with M2000 to investigate the gene expression levels of TNF-a, IL-6, IL-22, MYD88 and TLR2 molecules in them using Real-time PCR.
Results: This study data represented a higher gene expression in all target molecules in the RA patients in comparison to the healthy individuals. Furthermore, the outcomes showed that after 12 weeks of therapy with M2000, the gene expression levels of inflammatory factors TNF-a, IL-6, IL-22, MYD88 and TLR2 decreased significantly in treated patients compared to before therapy. The gene expression results were following the clinical and paraclinical assessments. Conclusion: In conclusion, M2000 as a newly approved anti-inflammatory and immunosuppressive drug, can be proposed as a therapeutic agent in RA patients.
Abstract
Introduction: Rheumatoid arthritis (RA) is a progressive multifactorial inflammatory disorder. According to numerous evidence, pro-inflammatory markers such as TNF-a, IL-6, IL-22, MYD88 and TLR2 play a substantial role in the pathogenesis and persistence of this disease. B-D-Mannuronic acid (M2000) is a new immunosuppressive drug whose therapeutic effects have been approved in several clinical trials and the results of the phase III clinical trial of this drug in RA patients were potent and efficient. Therefore, the present investigation was designed to evaluate its anti-inflammatory effects on the expression of mentioned factors in RA patients.
Material and methods: This research was carried out on 12 healthy individuals and 12 patients with RA and M2000 was administered to the patients orally at a dose of 500 mg twice daily for 12 weeks. The peripheral blood mononuclear cells (PBMCs) were collected from the patients before and after treatment with M2000 to investigate the gene expression levels of TNF-a, IL-6, IL-22, MYD88 and TLR2 molecules in them using Real-time PCR.
Results: This study data represented a higher gene expression in all target molecules in the RA patients in comparison to the healthy individuals. Furthermore, the outcomes showed that after 12 weeks of therapy with M2000, the gene expression levels of inflammatory factors TNF-a, IL-6, IL-22, MYD88 and TLR2 decreased significantly in treated patients compared to before therapy. The gene expression results were following the clinical and paraclinical assessments. Conclusion: In conclusion, M2000 as a newly approved anti-inflammatory and immunosuppressive drug, can be proposed as a therapeutic agent in RA patients.
Keywords
mannuronic acid, M2000, rheumatoid arthritis, TNF-a, IL-6, IL-22, MYD88, TLR2
About this articleTitle
The genes expression status of inflammatory determinants following the oral administration of Mannuronic acid in patients with rheumatoid arthritis
Journal
Issue
Article type
Original article
Pages
41-49
Published online
2023-03-15
Page views
2156
Article views/downloads
296
DOI
Bibliographic record
Medical Research Journal 2023;8(1):41-49.
Keywords
mannuronic acid
M2000
rheumatoid arthritis
TNF-a
IL-6
IL-22
MYD88
TLR2
Authors
Saiedeh Omidian
Arman Ahmadzadeh
Zahra Rezaieyazdi
Hossein Soleymani-Salehabadi
Anis Barati
Atousa Khalatbari
Abbas Mirshafiey
References (55)- Singh JA, Saag KG. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2016; 68(1): 1–26.
- Tavasolian F, Abdollahi E, Rezaei R, et al. Altered expression of microRNAs in rheumatoid arthritis. Journal of cellular biochemistry. 2018; 119(1): 478–487.
- Roberts CA, Dickinson AK, Taams LS. The interplay between monocytes/macrophages and CD4(+) T cell subsets in rheumatoid arthritis. Front Immunol. 2015; 6: 571.
- Mahmoudi M, Aslani S, Fadaei R, et al. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int J Rheum Dis. 2017; 20(3): 287–297.
- El-Rharras S, Minichiello E, Semerano L, et al. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. Expert Opin Investig Drugs. 2014; 23(7): 979–999.
- Neog MK, Sultana F, Rasool M, et al. A novel therapeutic approach targeting rheumatoid arthritis by combined administration of morin, a dietary flavanol and non-steroidal anti-inflammatory drug indomethacin with reference to pro-inflammatory cytokines, inflammatory enzymes, RANKL and transcription factors. Chem Biol Interact. 2015; 230: 58–70.
- Fukui S, Iwamoto N, Takatani A, et al. M1 and M2 Monocytes in Rheumatoid Arthritis: A Contribution of Imbalance of M1/M2 Monocytes to Osteoclastogenesis. Front Immunol. 2017; 8: 1958.
- Smolen JS, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol. 2012; 8(4): 235–243.
- Malemud CJ. Chondrocyte apoptosis in rheumatoid arthritis: Is preventive therapy possible? Immunotherapy (Los Angel). 2015; 1(1).
- Hunter C, Jones S. IL-6 as a keystone cytokine in health and disease. Nature Immunology. 2015; 16(5): 448–457.
- Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Review of Clinical Immunology. 2017; 13(6): 535–551.
- Müller N, Schulte DM, Türk K, et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res. 2015; 56(5): 1034–1042.
- Fleischer S, Ries S, Shen P, et al. Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. Eur J Immunol. 2018; 48(1): 194–203.
- Mitra A, Raychaudhuri S, Raychaudhuri S. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. Cytokine. 2012; 60(1): 38–42.
- Zhao M, Li Y, Xiao W. Anti-apoptotic effect of interleukin-22 on fibroblast-like synoviocytes in patients with rheumatoid arthritis is mediated via the signal transducer and activator of transcription 3 signaling pathway. Int J Rheum Dis. 2017; 20(2): 214–224.
- Xie Q, Huang C, Li J. Interleukin-22 and rheumatoid arthritis: emerging role in pathogenesis and therapy. Autoimmunity. 2015; 48(2): 69–72.
- Eser B, Sahin N. Evaluation of tool-like receptor-2 and 4 and interleukin-6 gene expressions in Turkish rheumatoid arthritis patients. Clin Rheumatol. 2016; 35(11): 2693–2697.
- Sahaya Sa, Devi R, Esther Na, et al. Toll-like receptors: the gateway of immune system. 2018.
- LeBel M, Egarnes B, Brunet A, et al. Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists. Arthritis Res Ther. 2016; 18(2): 10–257.
- Karim AF, Reba SM, Li Q, et al. TLR2 engagement on CD4(+) T cells enhances effector functions and protective responses to Mycobacterium tuberculosis. Eur J Immunol. 2014; 44(5): 1410–1421.
- Good D, George T, Watts B. Toll-like receptor 2 is required for LPS-induced toll-like receptor 4 signaling and inhibition of ion transport in renal thick ascending limb. Journal of Biological Chemistry. 2012; 287(24): 20208–20220.
- Quero L, Tiaden AN, Hanser E, et al. TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 phenotype. Arthritis Res Ther. 2017; 19(1): 245.
- Howard M, Smith R. Rheumatoid arthritis treatment & management. AMed Scape. 2018.
- Murdaca G, Spanò F, Contatore M, et al. Infection risk associated with anti-TNF-α agents: a review. Expert Opinion on Drug Safety. 2015; 14(4): 571–582.
- Mirshafiey A, Cuzzocrea S, Rehm B, et al. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol. 2005; 61(5): 435–441.
- Mirshafiey A, Rehm B, Sotoude M, et al. Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis. Immunopharmacol Immunotoxicol. 2007; 29(1): 49–61.
- Ahmadi H, Jamshidi A, Gharibdoost F, et al. A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology. 2018; 26(3): 737–745.
- Rezaieyazdi Z, Farooqi A, Soleymani-Salehabadi H, et al. International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology. 2019; 27(5): 911–921.
- Fattahi M, Abdollahi M, Agha Mohammadi A. Preclinical assessment of beta-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharmacol Immunotoxicol. 2015; 37(6): 535–540.
- McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017; 389(10086): 2328–2337.
- Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388(10055): 2023–2038.
- McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol. 2016; 12(1): 63–68.
- Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012; 51: v3–v11.
- McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7(6): 429–442.
- Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(5): 986–1000.
- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011; 365(23): 2205–2219.
- Barcelos RP, Bresciani G, Cuevas MJ, et al. Diclofenac pretreatment modulates exercise-induced inflammation in skeletal muscle of rats through the TLR4/NF-κB pathway. Appl Physiol Nutr Metab. 2017; 42(7): 757–764.
- Huang Z, Jiang H, Zhao H, et al. Efficacy of parecoxib on the level of IL-6, CRP, and postoperative pain relief after percutaneous nephrolithotomy. Int J Clin Exp Med. 2016; 9(10): 19454–19460.
- Gorsky VA, Agapov MA, Khoreva MV, et al. The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis. Pancreas. 2015; 44(5): 824–830.
- Mirshafiey A, Matsuo H, Nakane S, et al. Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacology and Immunotoxicology. 2008; 27(2): 255–265.
- Mirshafiey A, Rehm B, Cuzzocrea S, et al. M2000, foundation of a new generation among NSAIDs. Letters in Drug Design & Discovery. 2005; 2(5): 412–423.
- Hosseini S, Abdollahi M, Azizi G, et al. Anti-aging effects of M2000 (β-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. J Basic Clin Physiol Pharmacol. 2017; 28(3): 249–255.
- Jahanbakhshi M, Babaloo Z, Mortazavi-Jahromi SS, et al. Modification of sexual hormones in rheumatoid arthritis patients by M2000 (β-D-mannuronic acid) as a novel NSAID with immunosuppressive property. Endocr Metab Immune Disord Drug Targets. 2018; 18(5): 530–536.
- Jafarnezhad-Ansariha F, Yekaninejad MS, Jamshidi AR, et al. The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line. Inflammopharmacology. 2018; 26(2): 375–384.
- Mohammed HA, Saboor-Yaraghi AA, Vahedi H, et al. Immunomodulatory effects of M2000 (β-D-Mannuronic acid) on TNF-α, IL-17 and FOXP3 gene expression in patients with inflammatory bowel disease. Int Immunopharmacol. 2017; 51: 107–113.
- Mirshafiey A, Taeb M, Mortazavi-Jahromi S, et al. Introduction of β- d -mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacological Reports. 2017; 69(5): 1067–1072.
- Vojdanian M, Hosseini M, Jamshidi AR, et al. The Anti-migraine effects of M2000 (β-D-mannuronic acid) on a patient with rheumatoid arthritis: case report. Curr Clin Pharmacol. 2017; 12(2): 127–130.
- Barati A, Jamshidi A. Effects of β-D-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, RORγt, IL4 and GATA3 gene expressions in rheumatoid arthritis patients. Drug design, development and therapy. 2017; 11: 1027–1033.
- Ahmadi H, Mahmoudi M, Gharibdoost F, et al. Targeting of circulating Th17 cells by β-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Inflammopharmacology. 2017; 26(1): 57–65.
- Ahmadi H, Jamshidi AR, Gharibdoost F, et al. e potent inhibitory effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on anti-cyclic citrullinated peptide antibodies, rheumatoid factor and anti-dsDNA antibodies in patients with rheumatoid arthritis. Curr Drug Discov Technol. 2017; 14(3): 206–214.
- Mortazavi-Jahromi SS, Jamshidi MM, Farazmand A, et al. Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions. Pharmacol Rep. 2017; 69(3): 479–484.
- Pourgholi F, Hajivalili M, Razavi R. The role of M2000 as an anti-inflammatory agent in toll-like receptor 2/microRNA-155 pathway. Avicenna journal of medical biotechnology. 2017; 9(1): 8–12.
- Fattahi MJ, Jamshidi A, Mahmoudi M, et al. Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trial. International Immunopharmacology. 2018; 54: 112–117.
- Aletaha S, Haddad L, Roozbehkia M, et al. M2000 (β-D-Mannuronic Acid) as a Novel Antagonist for Blocking the TLR2 and TLR4 Downstream Signalling Pathway. Scand J Immunol. 2017; 85(2): 122–129.
- Roozbehkia M, Mahmoudi M, Aletaha S, et al. The potent suppressive effect of β- d -mannuronic acid (M2000) on molecular expression of the TLR/NF-kB Signaling Pathway in ankylosing spondylitis patients. International Immunopharmacology. 2017; 52: 191–196.